Saturday, 5 September 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 7, 2026

Should You Buy Goldman Stock as Macro Clarity Rekindles Dealmaking?

View original at finance.yahoo.com
Should You Buy Goldman Stock as Macro Clarity Rekindles Dealmaking? U.S. dealmaking activity was muted in early 2025 as macroeconomic uncertainty and tariff-related concerns weighed on corporate and private equity decision-making…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Goldman topped global M&A rankings in 2025 by hitting $1.66 trillion in volume, advising on 40 megadeals and achieving market share of 36.4%

    80% confidence
  • Only 48% of private equity leaders felt confident pursuing M&A in Q1 2025, but confidence surged to 86% by year-end

    80% confidence
  • Zacks Consensus Estimate for Goldman's 2025 and 2026 earnings implies year-over-year growth of 20.8% and 12.8% respectively

    80% confidence
  • Nearly 69% of respondents describe the M&A environment as strong, and 90% expect deal activity to increase or remain steady

    80% confidence
  • OneGS 3.0 is a multi-year overhaul that embeds AI as a core operating capability rather than a standalone tool

    80% confidence
  • Company targets mid-term goals of 14-16% return on equity and 60% efficiency ratio

    80% confidence
  • Goldman Sachs carries Zacks Rank #2 (Buy) rating

    80% confidence
  • Asset Management unit intends to expand private credit portfolio to $300 billion by 2029

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Capital Surge Meets Investor Caution: Record Funding Rounds and Government Contracts Amid Valuation Skepticism
A single-week cluster of large AI/fintech funding rounds (Socure, Stability AI, Emerald AI, Generalist AI, Instinct, Gatik, Regent Craft) shows venture capital still pouring into AI infrastructure, identity, and autonomy plays, while Palantir's Army TITAN contract win coincided with a 6% stock drop — signaling that even flagship AI-defense revenue isn't immune to market reassessment of AI valuations. Efficiency-focused innovations like Multiverse Computing's model compression suggest the sector is also pivoting toward cost/inference economics as capital intensity draws scrutiny.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
The same metric (eps) for the same entity (Morgan Stanley & Co. LLC) reported for the identical fiscal period (Q1 2026) and observation date (2026-03-31) has two conflicting values: 3.43 USD_per_share vs 3.08 USD. This is not a temporal change — both observations claim to measure the same point in time. The ~10% discrepancy (0.35 USD difference) is material for a financial metric.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,273 source documents archived
Query this data → isubstrate.com
Should You Buy Goldman Stock as Macro Clarity Rekindles Dealmaking? — Source | Via News | ViaNews EU